Department of Cell Biology

Faculty of Medicine and Dentistry

University of Alberta, Canada

Email:[email protected]

Qualifications

1989-1993  Ph.D., Biochemistry, Simon Fraser University, Canada
1982-1985  M.S., Zoology, Academia Sinica, China
1978-1982  B.S., Biology, Peking University, China

Publications (Selected)

1. Wang, R. C., & Wang, Z. (2023). Precision medicine: disease subtyping and tailored treatment. Cancers, 15(15), 3837.
2. Maadi, H., & Wang, Z. (2022). A novel mechanism underlying the inhibitory effects of trastuzumab on the growth of HER2-positive breast cancer cells. Cells, 11(24), 4093.
3. Wang, R. C., & Wang, Z. (2022). Synchronization of cultured cells to G1, S, G2, and M phases by double thymidine block. In Cell-Cycle Synchronization: Methods and Protocols (pp. 61-71). New York, NY: Springer US.
4. Yu, J., Wang, Z., & Wang, Y. (2022). BrdU incorporation assay to analyze the entry into S phase. In Cell-Cycle Synchronization: Methods and Protocols (pp. 209-226). New York, NY: Springer US.
5. Wee, P., Wang, R. C., & Wang, Z. (2022). Synchronization of HeLa Cells to Various Interphases Including G1, S, and G2 Phases. In Cell-Cycle Synchronization: Methods and Protocols (pp. 87-97). New York, NY: Springer US.
6. Wang, Z. (2022). Cell cycle progression and synchronization: an overview. Cell-cycle Synchronization: methods and Protocols, 3-23.
7. Wee, P., Wang, R. C., & Wang, Z. (2022). Synchronization of HeLa cells to mitotic subphases. In Cell-Cycle Synchronization: Methods and Protocols (pp. 99-110). New York, NY: Springer US.
8. Wang, Z. (2021). Regulation of cell cycle progression by growth factor-induced cell signaling. Cells, 10(12), 3327.
9. Nami, B., Ghanaeian, A., Black, C., & Wang, Z. (2021). Epigenetic silencing of HER2 expression during epithelial-mesenchymal transition leads to trastuzumab resistance in breast cancer. Life, 11(9), 868.
10. Maadi, H., Soheilifar, M. H., Choi, W. S., Moshtaghian, A., & Wang, Z. (2021). Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers, 13(14), 3540.
11. Wang, Z. (2021). Drug resistance and novel therapies in cancers in 2019. Cancers, 13(4), 924.
12. Abdrabou, A., & Wang, Z. (2021). Regulation of the nuclear speckle localization and function of Rac1. The FASEB Journal, 35(2), e21235.
13. Wang, Z. (2021). Drug resistance and novel therapies in cancers in 2019. Cancers, 13(4), 924.
14. Zhang, W., Abdelrasoul, G. N., Savchenko, O., Abdrabou, A., Wang, Z., & Chen, J. (2020). Ultrasound-assisted magnetic nanoparticle-based gene delivery. Plos one, 15(9), e0239633.
15. Nami, B., Ghanaeian, A., & Wang, Z. (2020). Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer. bioRxiv, 2020-03.
16. Abdrabou, A., Brandwein, D., & Wang, Z. (2020). Differential subcellular distribution and translocation of seven 14-3-3 isoforms in response to EGF and during the cell cycle. International journal of molecular sciences, 21(1), 318.
17. Nami, B., Maadi, H., & Wang, Z. (2019). The effects of pertuzumab and its combination with trastuzumab on HER2 homodimerization and phosphorylation. Cancers, 11(3), 375.

Profile Details

https://www.ualberta.ca/en/medical-genetics/people/faculty/zhixiang-wang.html

https://scholar.google.com/citations?user=I8MONxkAAAAJ&hl=en

https://www.researchgate.net/profile/Zhixiang-Wang-4